Abbott Biotechnology Ltd.

Basf Aktiengesellschaft

Abbvie Biotechnology Ltd

Basf Aktiengesselschaft

David Schoenhaut

Boris Labkovsky

Tristan J Vaughan

Jochen G Salfeld

Zehra Kaymakcalan

Michael White

Brian Timothy McGuinness

Paul Sakorafas

John A Mankovich

Deborah J Allen

Andrew J Roberts

Alison Jane Wilton

Hendricus R J M Hoogenboom

Stefan Meuer

Burkhart Schraven

Sheldon Ratnofsky

Hendricus Renerus Hoogenboom

Alison J Wilton

Hendricus Rjm Hoogenboom

Hendricus R Hoogenboom

Brian T Mcguinness

Boris Labkovksy

Hendricus RJM Hoogenboom

Brian T Mcguiness

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &#x3b1; (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF&#x3b1;

Human antibodies that bind human TNF&#x3b1; and methods of using same

Methods of treating disorders using human antibodies that bind human TNF&#x3b1;

Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa

Methods for treating rheumatoid arthritis using human antibodies that bind human TNF&#x3b1;

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) are disclosed. These antibodies have high affinity for hTNF&agr; (e.g., K &equals;10 M or less), a slow off rate for hTNF&agr; dissociation (e.g., K &equals;10 sec or less) and neutralize hTNF&agr; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&agr; and for inhibiting hTNF&agr; activity, e.g., in a human subject suffering from a disorder in which hTNF&agr; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNFa

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr;(hTNF&agr;) are disclosed. These antibodies have high affinity for hTNF&agr; (e.g., K,&equals;10,M or less), a slow off rate for hTNF&agr; dissociation (e.g., K,&equals;10,sec,or less) and neutralize hTNF&agr; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&agr; and for inhibiting hTNF&agr; activity, e.g., in a human subject suffering from a disorder in which hTNF&agr; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF&agr;

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K.sub.d =10.sup.-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K.sub.off =10.sup.-3 sec.sup.-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF.alpha.

This invention relates to a newly identified protein useful for treating diseases of the immune system, methods for obtaining said protein, isolated nucleic acids encoding said protein, and methods for obtaining inhibitors of said protein. The protein of this invention is characterized by an apparent molecular weight of about 32 kD, an isoelectric point of about 4.0-4.5 and coprecipitation with CD45. The protein may also be used in in vitro or in vivo assays to identify inhibitors of T cell activation.

Nucleic acid molecules encoding PP32: a newly identified CD45-associated

pp: A newly identified CD45-associated protein

Growing community of inventors

Clifton, NJ, United States of America

David Schoenhaut